Learn about the role of HPV in cervical cancer
 
What's New


19. March 2014

Roche launches the cobas® Cdiff Test for detection of Clostridium difficile in markets accepting the CE mark 

New test expands menu for hospital-acquired infections testing on the cobas® 4800 System.

>more

12. March 2014

FDA Advisory Committee Unanimously Recommends Roche's HPV Test as Primary Screening Tool for Detection of Women at High Risk for Cervical Cancer 

The benefits of the cobas® HPV Test as a first-line primary screening tool in women 25 years and older to assess their risk of cervical cancer based on the presence of clinically relevant high-risk HPV DNA outweigh the risks.

>more


17. February 2014

Roche announces launch of the Dual Target HIV-1 Qualitative Test in markets accepting the CE mark

New test will help increase access for early infant HIV diagnosis

>more

 Diagnostic and Blood Screening Tests

 

Roche Molecular Diagnostics (RMD) offers a uniquely broad range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies.

 

RMD's tests and automated platforms are focused in the areas of virology, blood screening, HPV, genomics and oncology, microbiology and sexually transmitted infections. > more

 Contact

Contact your local sales representative for detailed information, questions and ordering.

 

 

 Browse Our Products

 Related Links